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Abstract 
 
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a recurrent and progressive 
disease that causes proximal, symmetrical extremity weakness. The disease is diagnosed using 
clinical features, electrophysiologic testing, albumino-cytological disassociation in the 
cerebrospinal fluid, and sural nerve plexus biopsy. However, because of the low sensitivity of 
diagnostic criteria and other similar neuropathies, including diabetic polyneuropathy (DPN), 
accurate diagnosis is difficult. Differentiating between these diseases is especially important as 
CIDP’s changes are reversible and DPN’s are not. Making this differentiation allows for 
symptomatic improvement in a patient’s quality of life that would not be achieved otherwise. 
Early recognition and treatment with modalities including corticosteroids, plasmapheresis, and 
IVIG, demonstrate improvement in a majority of patients. Primary care physicians (PCP) 
encounter patients with diabetes daily. It is important for PCPs to have a level of familiarity with 
CIDP to best care for those patients. 
 
Keywords 





In 1958, JH Austin identified a cohort of patients suffering from a recurrent, but steroid-
responsive, polyneuropathy.1 This was officially named chronic inflammatory demyelinating 
polyneuropathy (CIDP) in 1975 by Peter Dyck.2 CIDP is the most common chronic 
inflammatory neuropathy affecting the peripheral nervous system3 and the most common 
treatable autoimmune neuropathy, accounting for 10% of patients referred to neurology clinics.4-
6 Prevalent in 1-9 cases per 100,000 individuals, it tends to occur in adults between 40-60 years 
old5,7 and affects males 58-66% of the time.3,4-7  
 
The disease can be seen in both humans and other mammals.4 It is characterized by progressive, 
primarily proximal, symmetrical extremity weakness, without muscle wasting.1,2,4-10 Like the 
motor defects, the associated sensory dysfunctions are non-length dependent neuropathies that 
result in numbness, paresthesia (described as a tingling or buzzing sensation), and proprioception 
issues.5-7 Neuropathic pain is rare and autonomic dysfunction is mild with symptoms usually 
confined to the bowel and bladder if present at all.5,7,8 Symptoms are routinely progressive but 
one third can have a relapsing and remitting phenotype with the peak severity of symptoms at 
eight weeks.1-3,5-10 Despite criteria from the American Academy of Neurology and European 
Federation of Neurology Society/Peripheral Nerve Society, diagnosis is difficult owing to their 
low sensitivities.3 These criteria depend upon clinical features, electrophysiologic testing, 
albumino-cytological disassociation in the cerebrospinal fluid (CSF), sural nerve plexus biopsy 
and MRI.6,8 Atypical forms of CIDP further compound this diagnostic dilemma, with many 
patients carrying the diagnosis without fulfilling the criteria.1,7,11 Diagnostic certainty is 
complicated by CIDP mimics (Table #1) and other common concomitant neurologic conditions 
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like diabetic polyneuropathy (DPN). Familiarity with the pathology and clinical course of CIDP 
is important for primary care physicians (PCPs) to make the correct diagnosis and ensure rapid 
and appropriate treatment.  
 
Demyelinating Polyneuropathy Signs and Symptoms 
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A 49-year-old male with chronic low back pain and a seven-year history of diabetic peripheral 
neuropathy resulting from twenty years of poorly controlled type 2 diabetes, presented to his 
PCP complaining of a two-week history of worsening pain and weakness. Prior to this, the 
patient had complaints of progressive neuropathic pain and failed multiple trials of medications, 
including opiates. Ultimately, he had a spinal cord stimulator implanted. The patient reported 
“lightning [shooting] down both legs” causing weakness with weight-bearing as well as falls. 
Following the appointment with his PCP, the patient was immediately sent to pain management 
for the evaluation of the stimulator. CT imaging of the lumbar and thoracic spine was ordered at 
the request of the pain management specialist. This revealed no acute changes and appropriate 
placement of the spinal cord stimulator. Neurology was consulted and ordered an 
electromyogram and nerve conduction study of the lower extremities. The initial impression was 
severe diabetic neuropathy.  
 
The neurologist referred the patient to a colleague and repeat electrophysiologic testing at six 
weeks following the initial presentation showed ‘very severe chronic axonal sensory-motor 
neuropathy’ and further testing was recommended of the upper extremities, which demonstrated 
a demyelinating neuropathy. Evaluation by neurology included thyroid levels, RPR, vitamin 
B12, copper, ganglioside antibodies and serum electrophoresis, which returned as normal. 
Sedimentation rate, homocysteine, methyl-malonic acid, and free Kappa/Lambda light chains 
were elevated, while vitamin B6 and zinc levels were low. A normal opening pressure of 33 
mmHg on lumbar puncture was obtained. Red and white blood cells were normal within the 
cerebrospinal fluid (CSF), and both glucose (90 mg/dL) and protein (55 mg/dL) were elevated. 
Electrophysiologic testing of the bilateral upper extremities was consistent with CIDP (Figures 
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Figure 1: Nerve Conduction Study - Motor (left column) and F-Wave (right column) 
complexes for bilateral median nerves. The motor nerve conduction (MNC) of bilateral 
median nerves was tested using the abductor pollicis brevis (APB). Amplitude is related to the 
number of axons in a nerve, therefore a reduction in amplitude indicates a loss of neurons. 
Latency is a marker of time and when prolonged, signifies a demyelinating process. Conduction 
velocity, a measure of speed, is affected by both axonal loss and demyelination. F waves 
evaluate proximal demyelination by looking at conduction speeds. F waves are created when a 
stimulus is applied to a distal motor nerve. The impulse travels antidromically from peripheral 
nerve to anterior horn cell and is bounced back down the motor neuron to create muscle 
contraction. In early disease course, F waves may be normal. In mid-course of disease, F waves 
will show delayed latency. In late/severe disease, F waves may be absent. In our patient, the left 
median motor amplitude was reduced with a prolonged distal motor latency and a moderately 
slow conduction velocity in the demyelinating range. The left median F wave latency was very 
prolonged, indicating proximal demyelination. The right median motor amplitude was 
moderately reduced, with a prolonged distal motor latency and very slowed conduction velocity 
registering in the demyelinating range. The right median F wave latency was normal.  
12






Figure 2: Nerve Conduction Study - Motor (left column) and F-Wave (right column) 
complexes for bilateral ulnar nerves. The motor nerve conduction (MNC) of bilateral ulnar 
nerves was tested using the abductor digiti minimi (ADM). The left ulnar motor amplitude was 
very reduced with a prolonged distal motor latency and moderately slow conduction velocities 
indicating demyelination and loss of axons. The left ulnar F wave response was absent indicating 
late/severe disease progression. The right ulnar motor amplitude demonstrated a conduction 
block at the elbow, with prolonged distal motor latency and slowed conduction velocities in the 
demyelinating range. A conduction block occurs when the loss of myelin thickness is great 
enough to lead to saltatory conduction failure and severely prolonged motor latencies and 
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His chronic kidney disease and poorly controlled diabetes limited the use of IVIG and high-dose 
steroids. Therefore, he began treatment with five inpatient sessions of plasma exchange (PLEX) 
and physical therapy. Within two weeks, increased lower extremity strength, decreased pain, and 
unassisted ambulation was noted. One month after the initial treatment, he received a second 
course of five PLEX treatments. By six-weeks following the second treatment, the patient noted 
continued improvement in symptoms with decreased pain and increased range of motion. This 
lasted three months. A functional decline in strength and an increase in limb paresthesias 
necessitated a third round of PLEX treatments. The patient improved, but not to his previous 
level of functioning, and left the hospital requiring a walker to ambulate. One month later, the 




CIDP Pathophysiology and Diagnosis 
 
CIDP is classified as a demyelinating process of the peripheral nervous system.2,4-6,10,13 The 
precise pathological mechanisms are still largely unknown despite treatment based studies 
rendering genetic, metabolic, and toxic causes unlikely.12 Cell-mediated and humoral immune-
mediated inflammation directed against the peripheral nerve epitopes of myelin sheath Schwann 
Cells are implicated for this polyradiculoneuropathy.1,3,3 Cell-mediated and humoral influenced 
T cells affect the permeability of the blood-nerve barrier, allowing antibodies to attack the 
endoneurium.6 The Schwann cells begin to react to this damage and lay down a new myelin 
sheath. This demyelinating-remyelinating picture primarily targets proximal peripheral nerves, 
specifically spinal roots, proximal nerve trunks, and major plexuses.2,4-6,12,13  
 
Despite only 50%-60% of patients with CIDP fulfilling one of the over fifteen established 
criteria,2,5,7 components of these criteria do have merit and can help aid the physician in early 
diagnosis. One such component is electrophysiologic testing (Table #2), which demonstrates 
primary demyelination by reduced conduction velocities, prolonged distal motor latencies, 
prolonged F wave latencies, and a patchy temporal dispersion, or conduction blockade.2,4-6,13 
Secondly, CSF studies reveal an albumin-cytologic disassociation, with increased protein levels 
from damage to the blood-CSF barrier at proximal nerve roots.5,6,10,14 To further emphasize the 
inflammatory nature of CIDP, fibrinogen, haptoglobin and prealbumin, all indicators of chronic 
and acute inflammation, are seen in the CSF.14 Finally, a nerve biopsy of affected proximal 
sensory nerves is diagnostic but should be saved for last resort.5,6,12,13 Microscopic evaluation of 
biopsies from patients show macrophage associated demyelination-remyelination, endoneurial 
infiltrates of CD8+ and CD4+ T cells, hypermyelination formation of ‘onion bulbs’, axonal 
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Table #2: EMG comparison of different demyelinating polyneuropathies. LLN = lower limit 
normal; ULN = upper limit normal. Conduction Velocities = Segment Distance (mm) per change 
of Segment Latency (msec). Distal Motor Latencies (msec) = the time from stimulus to the 
distal motor response is recorded. Distal motor nerves have tortuous routes. H Wave: the 
electrical equivalent of the monosynaptic stretch reflex. Stimulate 1a fibers to dorsal root 
ganglion to anterior horn cells to alpha motor axon to muscle. F Wave: long latency muscle 
action potential seen after maximal stimulation to a nerve. Stimulus travels through motor fibers 
to anterior horn cells, depolarized at critical time, to alpha motor axon to small late motor/muscle 
response. Seen AFTER the direct motor response. Used to test proximal nerve abnormalities. 
Temporal Dispersion = Seen in incomplete demyelination allowing conduction at different 
velocities. (CMAP) compound motor action potential = activation of muscle fibers in a target 
muscle supplied by the nerve. 
15
Dever et al.: Chronic Inflammatory Demyelinating Polyneuropathy
Published by Marshall University's Joan C. Edwards School of Medicine, 2020
 
Diagnostic Mimics of CIDP 
 
Differentiating between the diagnosis of CIDP and the alphabet soup of other immune-mediated 
demyelinating neuropathies (Table #1) is difficult due to the overlapping, and sometimes 
inconsistent, set of neurologic symptoms.2,5 Guillain-Barre syndrome (GBS) is the most 
frequently pursued diagnostic option but can be differentiated best by the time frame and course 
in which the symptoms develop.5,10,12 GBS reaches its maximum severity in a four-week 
monophasic course,8,15 whereas CIDP reaches its maximum severity through either a progressive 
(two-thirds of cases) or a relapsing-remitting course (one-third of cases) in eight weeks.1,4-9 
Adding another layer of confusion, treatment-related failures of GBS can mimic the relapsing-
remitting course of CIDP.15 Two atypical variants of CIDP further complicate using the clinical 
course for diagnosis. Acute CIDP (a-CIDP), occurring in 16% of CIDP patients,15 and acute 
inflammatory demyelinating polyneuropathy (AIDP), exhibit similar symptoms, but with peak 
severity closer to four weeks.4,7,8 The nature of symptoms can also vary. GBS tends to exhibit 
more severe symptoms like respiratory failure and will be more likely to exhibit autonomic 
dysfunction and cranial nerve involvement.7,12 Patients with A-CIDP, AIDP and CIDP rarely 
present with these findings, although AIDP tends to be the most severe of the three.7,8,15 
Diagnostic overlap can be seen with electrophysiologic testing and CSF studies (Table #2),8,9,14,15 
but GBS tends to develop after infections, especially with Campylobacter jejuni and Zika 
virus.6,15 
 
Diabetic Polyneuropathy – compounding diagnostic certainty 
 
In this case, the diagnosis of the patient’s longstanding neuropathy was further confounded by 
the presence of diabetes, which affects 9% of the general population and 29.6% of those people 
65 years and older.6 Severe or uncontrolled cases of diabetes can lead to diabetic peripheral 
neuropathy (DPN).7 DPN, the most common peripheral polyneuropathy, results from axonal 
damage due to glycemic mediated metabolic derangement. This glucose-mediated process is 
thought to disturb neuronal metabolism, alter blood supply to the vasa nervosum, and inflict 
damage to the Schwann Cells of the nerve sheath.2 An autoimmune response can occur through 
non-enzymatic glycosylation of myelin, whereby this glycosylation promotes recognition and 
degradation by macrophages.1 While the pathology is different, DPN shares some symptoms 
with CIDP, not only making it challenging to distinguish between the two, but also masking and 
augmenting symptoms of CIDP. Clues to differentiate the two clinical pictures include DPN’s 
gradual (greater than one year) progression of axonal length-dependent symptoms, which tend to 
be mostly sensory in nature and predominately affect distal lower extremities.2  
 
Electrophysiologic results (Table #2) and protein levels in the CSF create further overlap due to 
similar findings.2,6 Another problem with DPN is its ability to mask concomitant CIDP as the 
patient concentrates more on their pain than the change in weakness and other neurologic 
symptoms.6 A combination should be suspected in an older population, especially when the 
symptoms and conduction velocities of DPN are out of proportion for the duration of diabetes 
and level of diabetic control.2,3,6 This requires a certain level of clinical suspicion based upon 
comparisons to neuropathic symptom burdens of similar patients with only diabetes. While 
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diagnostic criteria are less predictive, decreasing the likelihood of treatment initiation, treatment 
success rates in patients with DPN and CIDP combined are similar to those of CIDP alone.3,6 
 
Importance of Rapid and Correct Diagnosis 
 
The most important reason to correctly differentiate a diabetic patient with concomitant CIDP 
from worsening DPN is that unlike irreversible DPN, CIDP is a treatable condition.2 The case-
patient had a prolonged course of sensory symptoms related to DPN. Worsening neuropathic 
symptoms and weakness occurred around the implantation of the spinal cord stimulator. It is 
unclear how long the patient’s CIDP was masked by his DPN. It wasn’t until the new neurologic 
symptoms, initially attributed to the stimulator, that the diagnosis was uncovered by the 
subsequent neurologic evaluation. Clues for earlier evaluation by the PCP could have been that 
the patient’s sensory symptoms were refractory to standard treatment, along with the 
development of motor dysfunction and proximal weakness. 
 
Treatment for CIDP patients with diabetes is guided by the treatment methodologies for CIDP 
alone, with goals to decrease handicap, reduce symptoms, and maintain long-term remission.5,7 
Traditional therapy for CIDP includes corticosteroids, plasmapheresis, and IVIG. Improvement 
is seen in 50-80% of patients.5 Corticosteroid benefit is similar for progressive and relapsing-
remitting types and is effective at 60mg daily doses of Prednisone.5 Responses are noted as early 
as two months, peaking in efficacy at six months. There is a seventy percent relapse after 
discontinuation.5,6 However, because corticosteroids can worsen glycemic control in patients 
with diabetes, as well as impact osteoporosis, gastritis, cataracts, mood changes, glaucoma and 
fluid retention, IVIG and plasmapheresis are appealing options.5 Plasmapheresis can remove up 
to 45% of pathogenic humoral factors in a single exchange, affording a 33-80% response rate.5 
IVIG is usually the preferred treatment, especially for severe cases, and can modulate pathogenic 
autoantibodies, suppress pathogenic cytokines, reduce complement deposition, and alternate 
pathogenic T cell function.5 There is a 50-75% response rate within a few weeks, which results 
in improved strength, functional disability and quality of life.5 Complications for these treatments 
are the expense, time consumption, availability, and side effects ranging from headache, rash and 




CIDP in the presence of DPN is a difficult diagnosis for a PCP to suspect. Recognizing it from 
other potential neuropathies increased the likelihood of appropriate treatment of symptoms and 
improvement in the patient’s quality of life. Early diagnosis requires clinical suspicion. While 
specialist involvement is essential, PCPs usually will be the first to encounter this pathology and 
differentiate it from the multiple mimics. PCPs should consider CIDP superimposed on DPN 
when a diabetic patient has proximal weakness and sensory symptoms refractory to usual 
treatments and/or are disproportionately greater than would be expected for the duration of 
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